ReviewThe oncologist2011

Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.

Hilda Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.